Humira (adalimumab)

Published Online: Sunday, January 1, 2006

Abbott Laboratories (Chicago, Ill) recently received FDA approval of Humira for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis. The product is also indicated for reducing the signs and symptoms, including major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderate-to-severe active rheumatoid arthritis. The recommended dosage regimen for Humira for adult patients with rheumatoid arthritis or psoriatic arthritis is 40 mg administered every other week as a subcutaneous injection. The product is supplied in single- use, 1-mL prefilled glass syringes as a sterile, preservative-free solution for subcutaneous administration. For more information, visit www.humira.com.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A